Loading...
Loading...
GANX| Name | Value |
|---|---|
| Revenues | 140.1K |
| Cost of Revenue | 0.0K |
| Gross Profit | 140.1K |
| Operating Expense | 4,561.2K |
| Operating I/L | -4,561.2K |
| Other Income/Expense | -35.2K |
| Interest Income | 222.0K |
| Pretax | -4,596.4K |
| Income Tax Expense | 78.1K |
| Net Income/Loss | -4,674.5K |
Gain Therapeutics, Inc. is a biotechnology company specializing in developing therapies for rare genetic diseases and neurological disorders caused by protein misfolding. The company utilizes its Site-Directed Enzyme Enhancement Therapy platform to identify proprietary small molecules that bind allosteric sites on misfolded proteins, restore protein folding, and treat diseases such as Morquio B, GM1 gangliosidosis, neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases.
